<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9683">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05692674</url>
  </required_header>
  <id_info>
    <org_study_id>SPHIC-TR-BCa2022-02</org_study_id>
    <nct_id>NCT05692674</nct_id>
  </id_info>
  <brief_title>A Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Breast Cancer With Implantation Reconstruction</brief_title>
  <official_title>A Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Breast Cancer With Implantation Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Proton and Heavy Ion Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Proton and Heavy Ion Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of breast reconstruction failure after conventional photon radiotherapy for&#xD;
      breast cancer is about 18.7%. At present, there is limited data on proton radiotherapy for&#xD;
      post operative breast cancer with implantation reconstruction. Proton radiotherapy for breast&#xD;
      cancer can significantly reduce the radiation dose of the ipsilateral heart and lung, thereby&#xD;
      reducing the incidence of cardiac events and radiation pneumonia. This study is aimed at the&#xD;
      study of adjuvant hypofractionated intensity-modulated proton radiotherapy for post operative&#xD;
      breast cancer with implantation reconstruction. It can provide an ideal treatment option for&#xD;
      such patients to effectively protect the heart and lungs without increasing the failure rate&#xD;
      of breast reconstruction after adjuvant radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 10, 2023</start_date>
  <completion_date type="Anticipated">September 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2028</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the failure rate of breast reconstruction after hypofractionated proton radiotherapy</measure>
    <time_frame>within 2 years after hypofractionated proton radiotherapy</time_frame>
    <description>Reoperation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute and late toxicities</measure>
    <time_frame>within 5 years after radiotherapy</time_frame>
    <description>Treatment related toxicity assessed by CTCAE v4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor local control rate, overall survival rate and progression free survival rate</measure>
    <time_frame>within 5 years after radiotherapy</time_frame>
    <description>The Ipsilateral breast and regional lymph nodes recurrence, death and progression</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>adjuvant hypofractionated intensity-modulated proton radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CTV1: chest wall ± regional lymph drainage area, proton therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>adjuvant hypofractionated intensity-modulated proton radiotherapy</intervention_name>
    <description>CTV1: chest wall ± regional lymph drainage area, 40.05Gy (RBE) in 15 fractions with proton radiotherapy;</description>
    <arm_group_label>adjuvant hypofractionated intensity-modulated proton radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1: Patients with pathologically confirmed breast cancer&#xD;
&#xD;
             2: Indications: patients who need adjuvant radiotherapy after mastectomy and implant&#xD;
             reconstruction&#xD;
&#xD;
             3: No distant metastasis&#xD;
&#xD;
             4: Had no chest and breast radiotherapy history&#xD;
&#xD;
             5: Between the ages of 18 and 80&#xD;
&#xD;
             6: ECOG general status score is 0-2,There are no serious pulmonary hypertension,&#xD;
             cardiovascular disease, peripheral vascular disease, serious chronic heart disease and&#xD;
             other complications that may affect the radiotherapy&#xD;
&#xD;
             7: Non pregnancy (confirmed by serum or urine β- HCG test) or lactating women&#xD;
&#xD;
             8: The patient must sign the informed consent form for receiving radiotherapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1: No pathological confirmation；&#xD;
&#xD;
             2: Distant metastasis；&#xD;
&#xD;
             3: Had chest and breast radiotherapy history&#xD;
&#xD;
             4: Organs at risk could not achieve safe dose&#xD;
&#xD;
             5: Pregnancy (confirmed by serum or urine β- HCG test) or lactating women&#xD;
&#xD;
             6: Poor general health status, i.e. KPS&lt;70, or ECOG&gt;2&#xD;
&#xD;
             7: There are serious complications that may affect the radiotherapy, including: a)&#xD;
             unstable angina, congestive heart failure and myocardial infarction requiring&#xD;
             hospitalization in the past 6 months； b) Acute bacterial or systemic fungal&#xD;
             infection；c) Chronic obstructive pulmonary disease exacerbation or other respiratory&#xD;
             diseases need hospitalization； d) Patients with immunosuppression；e) With connective&#xD;
             tissue disease, such as active scleroderma or lupus and other contraindications to&#xD;
             radiotherapy；&#xD;
&#xD;
             8: Unable to understand the purpose of treatment or unwilling/unable to sign informed&#xD;
             consent.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Proton and Heavy Ion center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201321</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Li</last_name>
      <phone>+86 021-38296666</phone>
      <email>ping.li@sphic.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Cihang Bao</last_name>
      <phone>+86 021-38296666</phone>
      <email>cihang.Bao@sphic.org.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 11, 2023</study_first_submitted>
  <study_first_submitted_qc>January 11, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2023</study_first_posted>
  <last_update_submitted>January 11, 2023</last_update_submitted>
  <last_update_submitted_qc>January 11, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Proton and Heavy Ion Center</investigator_affiliation>
    <investigator_full_name>Qing Zhang,MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>hypofractionated</keyword>
  <keyword>proton radiotherapy</keyword>
  <keyword>implantation reconstruction</keyword>
  <keyword>postoperative adjuvant radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

